Multi-omics integration defines an ECM-associated intratumoral heterogeneity signature enabling prognosis assessment and therapeutic stratification in hepatocellular carcinoma
Authors:
- 7 January 2026
- journal article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 340, 150143
Abstract
No abstract availableKeywords
Funding Information
- Guangxi Medical University (2024GXNSFBA010037)
- National Natural Science Foundation of China (82472741)
- National Natural Science Foundation of China (82403412)
- Natural Science Foundation of Guangxi Province
This publication has 44 references indexed in Scilit:
- Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targetsHepatology International, 2025
- S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF-kB/VEGF-D pathwayCancer Letters, 2024
- Tumor microenvironment signaling and therapeutics in cancer progressionCancer Communications, 2023
- Activated fibroblasts in cancer: Perspectives and challengesCancer Cell, 2023
- Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinomaDigestive and Liver Disease, 2022
- Implications of genetic heterogeneity in hepatocellular cancer2022
- FKBP10 Regulates Protein Translation to Sustain Lung Cancer GrowthCell Reports, 2020
- Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver CancerCancer Cell, 2019
- A Chaperone Complex Formed by HSP47, FKBP65, and BiP Modulates Telopeptide Lysyl Hydroxylation of Type I ProcollagenJournal of Bone and Mineral Research, 2017
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureCell, 2017